PO.6.132 A phase 2b study of afimetoran (BMS-986256) in patients with active systemic lupus erythematosus (SLE): optimization of a lupus clinical trial design
U Ranganathan(Bristol-Myers Squibb (United States)), Vaishali Shah(Bristol-Myers Squibb (United States)), E Culotta(Bristol-Myers Squibb (United States)), Sreeparna Banerjee(Middle East Technical University), MK Crow(Hospital for Special Surgery), Yun Shen(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), Steven Greenberg(Bristol-Myers Squibb (United States)), JT Merrill(Oklahoma Medical Research Foundation), Melanie Harrison(Bristol-Myers Squibb (United States)), Nikolay Delev(Bristol-Myers Squibb (Sweden))
Cited by 3
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
|Journal of Medicinal Chemistry|2014|112